Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.

Proton Rahman Wolf-Henning Boehncke Phillip J Mease Alice B Gottlieb Iain B McInnes May ShawiYanli WangShihong ShengAlexa P KollmeierElke TheanderJenny YuEvan LeibowitzA Marilise MarracheLaura C Coates

Published in: The Journal of rheumatology (2023)

The safety profile of GUS in TNFi-experienced patients was consistent with that in TNFi-naïve patients, which remained favorable for up to 2 years. [ClinicalTrials.gov: Phase 2 (NCT02319759), DISCOVER-1 (NCT03162796), DISCOVER-2 (NCT03158285), and COSMOS (NCT03796858)].

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
clinical trial
patient reported outcomes
open label
placebo controlled